Introduction
COVID-19 has the highest morbidity and mortality rates globally (Dong, Du, & Gardner, 2020). Emerging scientific and clinical evidence highlights that COVID-19 can result in subacute and long-term effects affecting multiple organ systems (Gupta et al., 2020). Persistent symptoms following COVID-19 include difficulty in breathing, chest discomfort, tiredness, discomfort in joints, cognitive dysfunction and significant decline in quality of life (Carfì, Bernabei, & Landi, 2020; Huang et al., 2021; Tenforde et al., 2020). These residual effects are thought to arise from cellular damage, an intense innate immune response with inflammatory cytokine release, and increased blood clotting induced by the virus (McElvaney et al., 2020; Sungnak et al., 2020; Tang et al., 2020). This complex interaction between viral pathogenesis and host immune responses need further more research and clinically comprehensive management to address both acute and chronic aspects of the disease.
Initial epidemiological data indicated that 8.2% of COVID-19 cases experienced severe respiratory issues that lead to Acute Respiratory Distress Syndrome(ARDS) (Ñamendys-Silva, 2020). Recent findings suggest that COVID-19 predominantly affects the lungs, causing diffuse alveolar epithelial destruction, hyaline membrane formation, capillary damage, bleeding, alveolar septal fibrous proliferation, and pulmonary consolidation (Mo et al., 2020; Shi et al., 2020). Extensive damage to alveolar epithelial and endothelial cells, along with secondary fibroproliferation, hints at potential long-term consequences such as lung fibrosis and pulmonary hypertension (Venkataraman & Frieman, 2017; Frija-Masson et al., 2020). These observations emphasize the need for careful evaluation of lung injury in patients after discharge (Mo et al., 2020). Additionally, SARS and MERS, indicates that patients experience lingering impairments for months or years after post discharge (Hui et al., 2005; Ong et al., 2005).
A meta- analysis found that 32% of individuals continued to feel fatigue for more than 12 weeks after diagnosis of COVID-19 (Ceban et al., 2022). Fatigue prevalence reports suggest that between 9% and 49% of patients experience fatigue four weeks after symptom onset, with about 30% still affected between 12 and 16 weeks (Sandler et al., 2021). COVID-19 significantly impacts the quality of life, especially in acute cases, among females, older adults, patients with severe disease, and those from low-income backgrounds (Poudel et al., 2021). Yoga therapy offers a potential adjunctive treatment to mitigate COVID-19 complications. Suganthy et al. (2023) reported significant improvements in biochemical, inflammatory, and haematological markers in COVID-19 patients at tertiary care hospitals after three months of Asana-Pranayama practice. Additionally, a review study highlighted the role of yoga and meditation in alleviating stress and enhancing immunity against infections like COVID-19 (Dalpati et al., 2022). Thus, yoga appears to be a promising strategy for boosting innate immunity and mental well-being, supporting its use as an adjunctive treatment for post-COVID symptoms (Basu-Ray et al., 2022).
This study aims to examine the effect of tailored yoga interventions on lung function, fatigue, and quality of life in patients experiencing post-COVID symptoms.
Materials and Methods
This protocol has been approved by the Institutional Ethics Committee from the authorities of the SVYASA deemed-to-be University and conducted in compliance with the Declaration of Helsinki. The written informed consent was obtained from individual participants before their recruitment to the study.
Participants:Sample size required for the study was calculated based on study of differences in aerobic exercise capacity between COVID-19 patient’s post-hospital discharge and comorbidity-matched controls. With an effect size of d=0.998d for aerobic exercise capacity, 15 participants per group was needed with an alpha= 5% and power=95%. To account for potential 20% loss to follow-up, 17 participants were recruited per group, totalling 34 participants (Raman et al., 2021).
Participants were recruited from SVYASA deemed-to-be University. Inclusion criteria: individuals over 18 years of age with confirmed COVID-19 diagnosed, either via reverse transcription-polymerase chain reaction (RT-PCR) on oropharyngeal-nasopharyngeal swab or Positive Rapid Antigen Test. Participants who have been hospitalised during COVID-19 infection; pregnant women; major surgery in the past 3 months; any other acute or chronic diseases like Chronic Obstructive Pulmonary Disease (COPD), Ischemic heart disease have been excluded in the study. Only participants who have mild acute infection at the time of diagnosis were recruited. Recruited participants were randomly allocated into two groups- 1. Yoga Group and 2. Control Group by using Computer- Generated Randomisation Sequence with a 1:1 allocation ratio.
Interventions: The integrated tele-based yoga intervention included breathing exercises, loosening exercises, pranayama and meditation techniques, specially designed to enhance immunity and overall health (Table 1) (Nagarathna, Nagendra, & Majumdar, 2020). This module was developed to address the needs of individuals recovering from COVID-19. The tele-based yoga program featured a 20-minute pre-recorded video. In the video, the first author (TL) demonstrated the practices in English and Hindi, while the second author (NSD) presented them in English and Kannada. Instructional language was tailored to the participants' preferences. Yoga sessions were scheduled based on participant availability, preferably between 6-8 am. The yoga group received the intervention for 15 days, with each session lasting 20 minutes. The sessions were conducted by certified Yoga and Naturopathy doctors with a Bachelor of Naturopathy and Yogic Sciences (BNYS), under medical supervision. Participants were required to attend at least 85% of the sessions (a minimum of 20 out of 24 scheduled sessions); those who did not meet this attendance requirement were withdrawn from the study. Participants in the control group were instructed to follow WHO guidelines for rehabilitation, specifically "Support for Rehabilitation: Self-Management after COVID-19" on a self-guided basis (Jimeno-Almazán et al., 2023).